Skip to main content

Table 1 Baseline study population characteristics (n = 43)

From: Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Age (yrs)

  median (range)

80 (70 – 92)

Sex (M/F)

36/7

ECOG PS (0/1/2)

0/16/27

Stage (IIIB/IV)

16/27

Smoke (never/past/current)

1/23/19

Serious co-morbid illnesses

  median (range)

3 (0 – 6)

Histology (n/%)

  Squamous cell carcinoma

24/43 (55.8%)

  Adenocarcinoma

11/43 (25.6%)

  Large-cell carcinoma

4/43 (9.3%)

  Undifferentiated

4/43 (9.3%)